Capstan Medical utilizes nitinol in its mitral heart valve implant and aims to merge surgical robotics with catheter-based technology for next-generation implants in the treatment of heart disease, a leading cause of death in the U.S.
Maggie Nixon, CEO of Capstan Medical, discusses the company's focus on nitinol, recent funding from Intuitive Ventures, and insights on leadership since becoming CEO.
Nitinol's unique properties like superelasticity and shape memory are beneficial for medical devices, allowing for easier placement and retrieval within the body, as well as permanent positioning for implants like heart valves.
Capstan emphasizes close collaboration with nitinol suppliers to ensure consistent quality and success in developing medical devices using the alloy.
Nixon highlights the importance of partnerships with manufacturers, specifically mentioning working closely with Admedes in Germany for their nitinol needs.
Having transitioned from a larger company to a smaller startup, Nixon values the energy, passion, and creativity of her team at Capstan and aims to maintain momentum for the company's growth.
Maintaining positive relationships with Intuitive Surgical, Capstan's former affiliations, Nixon recognizes the value of their network and collaboration.
Nixon advises on engaging with Intuitive Ventures by interacting with key team members at investment conferences, as they actively seek out innovative opportunities for investment.
Intuitive Ventures' consistent involvement in early-stage conferences presents opportunities for startups like Capstan Medical to connect with potential investors.
Capstan's approach to utilizing nitinol and securing funding from Intuitive Ventures demonstrates their commitment to advancing medical technology and addressing critical healthcare needs.